Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. 2009

Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Hacettepe University, 06100 Sihhiye, Ankara, Turkey. onesrin@hacettepe.edu.tr

A novel series of 2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazole and 2-substituted thiocarbamoyl-3,3a,4,5,6,7-hexahydro-2H-indazoles derivatives were synthesized and investigated for the ability to inhibit the activity of the A and B isoforms of monoamine oxidase (MAO). The target molecules were identified on the basis of satisfactory analytical and spectra data (IR, (1)H NMR, (13)C NMR, (2)D NMR, DEPT, EI-MASS techniques and elemental analysis). Synthesized compounds showed high activity against both the MAO-A (compounds 1d, 1e, 2c, 2d, 2e) and the MAO-B (compounds 1a, 1b, 1c, 2a, 2b) isoforms. In the discussion of the results, the influence of the structure on the biological activity of the prepared compounds was delineated. It was suggested that non-substituted and N-methyl/ethyl bearing compounds (except 2c) increased the inhibitory effect and selectivity toward MAO-B. The rest of the compounds, carrying N-allyl and N-phenyl, appeared to select the MAO-A isoform. The inhibition profile was found to be competitive and reversible for all compounds. A series of experimentally tested (1a-2e) compounds was docked computationally to the active site of the MAO-A and MAO-B isoenzyme. The autodock 4.01 program was employed to perform automated molecular docking. In order to see the detailed interactions of the docked poses of the model inhibitors compounds 1a, 1d, 1e and 2e were chosen because of their ability to reversibly inhibit the MAO-B and MAO-A and the availability of experimental inhibition data. The differences in the intermolecular hydrophobic and H-bonding of ligands to the active site of each MAO isoform were correlated to their biological data. Observation of the docked positions of these ligands revealed interactions with many residues previously reported to have an effect on the inhibition of the enzyme. Excellent to good correlations between the calculated and experimental K(i) values were obtained. In the docking of the MAO-A complex, the trans configuration of compound 1e made various very close interactions with the residues lining the active site cavity these interactions were much better than those of the other compounds tested in this study. This tight binding observation may be responsible for the nanomolar inhibition of form of MAOA. However, it binds slightly weaker (experimental K(i)=1.23 microM) to MAO-B than to MAO-A (experimental K(i)=4.22 nM).

UI MeSH Term Description Entries
D007191 Indazoles A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES. Indazole
D008930 Mitochondria, Liver Mitochondria in hepatocytes. As in all mitochondria, there are an outer membrane and an inner membrane, together creating two separate mitochondrial compartments: the internal matrix space and a much narrower intermembrane space. In the liver mitochondrion, an estimated 67% of the total mitochondrial proteins is located in the matrix. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p343-4) Liver Mitochondria,Liver Mitochondrion,Mitochondrion, Liver
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
February 2022, European journal of medicinal chemistry,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
March 2014, European journal of medicinal chemistry,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
October 2023, Future medicinal chemistry,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
December 2008, Chemical & pharmaceutical bulletin,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
June 2013, Journal of neural transmission (Vienna, Austria : 1996),
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
March 2006, Chemical biology & drug design,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
December 2012, Journal of medicinal chemistry,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
May 2016, European journal of medicinal chemistry,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
June 2020, Pharmacological reports : PR,
Nesrin Gökhan-Kelekçi, and O Ozgün Simşek, and Ayşe Ercan, and Kemal Yelekçi, and Z Sibel Sahin, and Samil Işik, and Gülberk Uçar, and A Altan Bilgin
November 2019, Bioorganic chemistry,
Copied contents to your clipboard!